Equities Analysts Offer Predictions for AVDL FY2027 Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDL - Free Report) - Analysts at HC Wainwright decreased their FY2027 earnings estimates for shares of Avadel Pharmaceuticals in a report issued on Wednesday, November 13th. HC Wainwright analyst O. Livnat now expects that the company will earn $1.67 per share for the year, down from their previous estimate of $1.74. HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Avadel Pharmaceuticals' FY2028 earnings at $1.88 EPS.

Several other equities research analysts also recently weighed in on AVDL. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price objective on shares of Avadel Pharmaceuticals in a report on Tuesday. Oppenheimer upped their price target on shares of Avadel Pharmaceuticals from $29.00 to $30.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $24.43.

Avadel Pharmaceuticals Stock Down 3.6 %

NASDAQ:AVDL traded down $0.43 during mid-day trading on Thursday, reaching $11.59. 2,349,258 shares of the stock were exchanged, compared to its average volume of 1,187,195. The stock has a market capitalization of $1.12 billion, a P/E ratio of -14.67 and a beta of 1.47. Avadel Pharmaceuticals has a 1 year low of $10.39 and a 1 year high of $19.09. The company has a 50 day simple moving average of $13.62 and a 200-day simple moving average of $15.09.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. Avadel Pharmaceuticals had a negative net margin of 52.53% and a negative return on equity of 92.12%. The company had revenue of $50.00 million during the quarter, compared to the consensus estimate of $48.43 million. During the same quarter in the prior year, the firm posted ($0.41) earnings per share. Avadel Pharmaceuticals's revenue for the quarter was up 624.6% on a year-over-year basis.

Institutional Investors Weigh In On Avadel Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Braidwell LP raised its position in Avadel Pharmaceuticals by 16.9% during the 3rd quarter. Braidwell LP now owns 3,388,939 shares of the company's stock worth $44,446,000 after buying an additional 490,300 shares during the last quarter. Verition Fund Management LLC purchased a new position in Avadel Pharmaceuticals during the third quarter worth about $262,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Avadel Pharmaceuticals in the third quarter valued at about $484,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Avadel Pharmaceuticals in the 3rd quarter valued at approximately $262,000. Finally, MetLife Investment Management LLC boosted its holdings in Avadel Pharmaceuticals by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 53,797 shares of the company's stock valued at $706,000 after purchasing an additional 30,313 shares in the last quarter. 69.19% of the stock is owned by institutional investors and hedge funds.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.